Хроническая сердечная недостаточность

ESC Guidelines for the diagnosis and treatment of acute and chronic
heart failure 2008. The Task Force for the Diagnosis and Treatment of
Acute and Chronic Heart Failure 2008 of the European Society of
Cardiology. Developed in collaboration with the Heart Failure
Association of the ESC (HFA) and endorsed by the European Society on
Intensive Care Medicine (ESICM). Eur J HeartFail. 2008;10 (10):933–989.

Фомин И. В. Артериальная гипертония в Российской Федерации –
последние 10 лет. Что дальше? Сердце. 2007;6 (3):1–6.

Фомин И. В. Эпидемиология хронической сердечной недостаточности в
Российской Федерации. В кн.: Хроническая сердечная недостаточность
[Агеев Ф. Т. и соавт.] – М.: ГЭОТАР-Медиа, 2021. – c. 7–77.

Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure
survey programme a survey on the quality of care among patients with
heart failure in Europe. Part 1: patient characteristics and diagnosis.
Eur Heart J. 2003;24 (5):442–463.

Lam C.S.P., Solomon S.D. The middle child in heart failure: heart
failure with mid-range ejection fraction (40–50%). Eur J Heart Fail
2021;16:1049–1055.

Щербинина Е.В., Бадин Ю.В., Вайсберг А.Р., и.др. Динамика
этиологических причин формирования ХСН в репрезентативной выборке
Нижегородской области за 9 лет наблюдения (1998–2007 гг.). Всероссийская
конференция ОССН: «Сердечная недостаточность, 2007 год» – М., 2007. – с.
38.

Фомин И. В., Бадин Ю. В., Егорова И. С., Щербинина Е. В. Гендерные
различия в распространенности сердечно-сосудистых заболеваний (данные
когортного исследования репрезентативной выборки Нижегородской области
1998–2002 гг.). Проблемы женского здоровья. 2006;1 (1):37–40.

Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart
failure: the Framingham Study. J Am Coll Cardiol 1993;22(4 Suppl
A):6A-13A.

Owan T.E.,Hodge D.O.,Herges R.M.,Jacobsen S.J.,Roger V.L.,Redfield
M.M. Trends in prevalence and outcome of heart failure with preserved
ejection fraction. N Engl J Med 2006;355:251–259.

Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The
survival of patients with heart failure with preserved or reduced left
ventricular ejection fraction: an individual patient data meta-analysis.
Eur Heart J2021;33:1750–1757.

Hogg K., Swedberg K., McMurray J. Heart Failure with preserved left
ventricular systolic function. Epidemiology, Clinical Characteristics,
and Prognosis. J Am Coll Cardiol. 2004;43 (3):317–327.

АгеевФ. Т.
Влияниесовременныхмедикаментозныхсредствнатечениезаболевания
«качествожизни» ипрогнозбольныхсразличнымистадиями хронической сердечной
недостаточности. Автореф. Дисс. Докт., Москва, 1997.

Терещенко С.Н., Жиров И.В., Нарусов О.Ю., Мареев Ю.В., Затейщиков
Д.А., Осмоловская Ю.Ф., Овчинников А.Г., Самко А.Н., Насонова С.Н.,
Стукалова О.В., Саидова М.А., Скворцов А.А., Шария М.А., Явелов И.С.
Диагностика и лечение хронической и острой сердечной недостаточности.
Кардиологическийвестник, 2021; № 2:3-33.

McMurray J. Clinical practice. Systolic heart failure. N Engl J Med.
2021;362 (3):228–238.

Chen J., Normand S.L., Wang Y., Krumholz H.M. National and regional
trends in heart failure hospitalization and mortality rates for Medicare
beneficiaries, 1998–2008. JAMA. 2021;306 (15):1669–1678.

Dunlay S.M., Redfield M.M., Weston S.A. et al. Hospitalizations
after heart failure diagnosis a community perspective. J Am Coll
Cardiol. 2009;54 (18):1695–1702.

Senni M., Gavazzi A., Oliva F., at al. In-hospital and 1-year
outcomes of acute heart failure patients according to presentation (de
novo vs. worsening) and ejection fraction. Results from IN-HF Outcome
Registry. Intern J Cardiol 2021;173:163-9.

Cowie M.R., Fox K.F., Wood D.A. et al. Hospitalization of patients
with heart failure: a population-based study. Eur Heart J. 2002;23
(11):877–885.

McAlister F.A., Teo K.K., Taher M. et al. Insights into the
contemporary epidemiology and outpatient management of congestive heart
failure. Am Heart J. 1999;138 (1 Pt 1):87–94.

Беленков Ю.Н., Овчинников А.Г., Агеев Ф.Т., Сербул В.М.
Гипертрофия левого
желудочка: роль ренин-ангиотензиновой системы. Кардиоваскулярная
терапия и профилактика 2008; №2:98-108.

Овчинников А.Г., Агеев Ф.Т., Свирида О.Н.
Патогенетический подход
к терапии пациентов с хронической сердечной недостаточностью и
сохраненной систолической функцией левого желудочка. Кардиологический
вестник 2021;№1: 33-39.

Pocock S.J., Wang D., Pfeffer M.A. et al. Predictors of mortality
and morbidity in patients with chronic heart failure. Eur Heart J.
2006;27 (1):65–75.

Komajda M., Carson P.E., Hetzel S. et al. Factors associated with
outcome in heart failure with preserved ejection fraction: findings from
the Irbesartan in Heart Failure with Preserved Ejection Fraction Study
(I-PRESERVE). Circ Heart Fail. 2021;4 (1):27–35.

Ketchum E.S., Levy W.C. Establishing prognosis in heart failure: |
multimarker approach. Prog Cardiovasc Dis. 2021;54 (2):86–96.

Ho K.K., Anderson K.M., Kannel W.B. et al. Survival after the onset
of congestive heart failure in Framingham Heart Study
subjects.Circulation. 1993;88 (1):107–115.

Даниелян М. О. Прогноз и лечение хронической сердечной
недостаточности (данные 20-и летнего наблюдения). Автореф. дис. канд.
мед.наук. Москва. 2001.

Бадин Ю. В., Фомин И. В. Выживаемость больных ХСН в когортной
выборке Нижегородской области (данные 1998–2002 годов.). Всероссийская
конференция ОССН: «Сердечная недостаточность, 2005 год» – М., 2005. – с.
31–32.

WedelH., McMurrayJ.J., LindbergMetal. Predictors of fatal and
non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in
Heart Failure (CORONA): incremental value of apolipoprotein A-1,
high-sensitivity C-reactive peptide and N-terminal proB-type natriuretic
peptide. Eur J Heart Fail. 2009;11 (3):281–291.

Allen L.A., Felker G.M., Pocock S. et al. Liver function
abnormalities and outcome in patients with chronic heart failure: dat|
from the Candesartan in Heart Failure: Assessment of Reduction in
Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11
(2):170–177.

Jackson C.E., Solomon S.D., Gerstein H.C. et al. Albuminuria in
chronic heart failure: prevalence and prognostic importance. Lancet
2009;374 (9689):543–550.

Felker G.M., Allen L.A., Pocock S.J. et al. Red cell distribution
width as a novel prognostic marker in heart failure: data from the CHARM
Program and the Duke Databank. J Am Coll Cardiol. 2007;50(1):40–47.

БеленковЮ. Н., ФоминИ. В., МареевВ. Ю. идр.
ПервыерезультатыРоссийскогоэпидемиологического исследования по
ХСН.Журнал Сердечная Недостаточность 2003;4 (1):26–30.

Агеев Ф. Т., Даниелян М. О., Мареев В. Ю. и др. Больные с
хронической сердечной недостаточностью в российской амбулаторной
практике: особенности контингента, диагностики и лечения (по материалам
исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность 2004;5
(1):4–7.

Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распространенность
хронической сердечной недостаточности в Европейской части Российской
Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность 2006;7
(1): 112–115.

Davie P., Francis C.M., Caruana L., Sutherland G.R., McMurray J.J.
Assessing diagnosis in heart failure: which features are any use? QJM
1997;90:335–339.

Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P.,
Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M.,
Sohanpal S., Sanders S., Hobbs FDR. Systematic review and individual
patient data meta-analysis of diagnosis of heart failure, with modelling
of implications of different diagnostic strategies in primary care.
Health Technol Assess 2009;13:1–207, iii.

Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., Van Velzen E.,
Wielders J.P., Zuithoff N.P., Rutten F.H., Hoes A.W. Clinical evaluation
of geriatric outpatients with suspected heart failure: value of
symptoms, signs, and additional tests. Eur J Heart Fail 2021;13:518–527.

Fonseca C. Diagnosis of heart failure in primary care. Heart Fail
Rev 2006;11:95–107.

Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd
A., Moons KGM, Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The
diagnostic value of physical examination and additional testing in
primary care patients with suspected heart failure. Circulation
2021;124:2865–2873.

Roberts E., Ludman A.J., Dworzynski K., Al-Mohammad A., Cowie M.R.,
McMurray J.J.V., Mant J. The diagnostic accuracy of the natriuretic
peptides in heart failure: systematic review and diagnostic
meta-analysis in the acute care setting. BMJ 2021;350:h910.

Zaphiriou A., Robb S., Murray-Thomas T., Mendez G., Fox K., McDonagh
T., Hardman S.M.C., Dargie H.J., Cowie M.R. The diagnostic accuracy of
plasma BNP and NTproBNP in patients referred from primary care with
suspected heart failure: results of the UK natriuretic peptide study.
Eur J Heart Fail 2005;7:537–541.

Fuat A., Murphy J.J., Hungin A.P.S., Curry J., Mehrzad A.A.,
Hetherington A., Johnston J.I., Smellie W.S.A., Duffy V., Cawley P. The
diagnostic accuracy and utility of a B-type natriuretic peptide test in
a community population of patients with suspected heart failure. Br J
Gen Pract 2006;56:327–333.

Yamamoto K., Burnett J.C., Bermudez E.A., Jougasaki M., Bailey K.R.,
Redfield M.M. Clinical criteria and biochemical markers for the
detection of systolic dysfunction. J Card Fail 2000;6:194–200.

Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G.,
Poole-Wilson P.A., Sutton G.C. Value of natriuretic peptides in
assessment of patients with possible new heart failure in primary care.
Lancet 1997;350:1349–1353.

Krishnaswamy P., Lubien E., Clopton P., Koon J., Kazanegra R.,
Wanner E., Gardetto N., Garcia A., DeMaria A., Maisel A.S. Utility of
B-natriuretic peptide levels in identifying patients with left
ventricular systolic or diastolic dysfunction. Am J Med
2001;111:274–279.

Kelder J.C., Cramer M.J., Verweij W.M., Grobbee D.E., Hoes
A.W.Clinical utility of three B-type natriuretic peptide assays for the
initial diagnostic assessment of new slow-onset heart failure. JCardFail
2021;17:729–734

van Riet E.E.S., Hoes A.W., Limburg A., Landman M.A.J., van der
Hoeven H., Rutten F.H. Prevalence of unrecognized heart failure in older
persons with shortness ofbreath on exertion. Eur J Heart Fail
2021;16:772–777.

Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd
A., Moons K.G.M., Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The
diagnostic value of physical examination and additional testing in
primary care patients with suspected heart failure. Circulation
2021;124:2865–2873.

Davie A.P., Francis C.M., Love M.P., Caruana L., Starkey I.R., Shaw
T.R., Sutherland G.R., McMurray J.J. Value of the electrocardiogram in
identifying heart failure due to left ventricular systolic dysfunction.
BMJ 1996;312:222.

Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K.,
Parrillo J.E., Calvin J.E. Utility of history, physical examination,
electrocardiogram, and chest radiograph for differentiating normal from
decreased systolic function in patients with heart failure.Am J Med
2002;112:437–445.

Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf
F.A., Rademakers F.E., Marino P., Smiseth O.A., De Keulenaer G.,
Leite-Moreira A.F., Borbely A., Edes I.,Handoko M.L., Heymans S.,
Pezzali N., Pieske B., Dickstein K., Fraser A.G.,Brutsaert D.L. How to
diagnose diastolic heart failure: a consensus statement on the diagnosis
of heart failure with normal left ventricular ejection fraction by the
Heart Failure and Echocardiography Associations of the European Society
of Cardiology. Eur Heart J 2007;28:2539–2550.

Marwick T.H., Raman S.V., Carrio´ I., Bax J.J. Recent developments
in heart failure imaging. JACC Cardiovasc Imaging 2021;3:429–439.

Dokainish H., Nguyen J.S., Bobek J., Goswami R., Lakkis N.M.
Assessment of the American Society of Echocardiography-European
Association of Echocardiography guidelines for diastolic function in
patients with depressed ejection fraction: an echocardiographic and
invasive haemodynamic study. Eur J Echocardiogr 2021; 12:857–864.

Kirkpatrick J.N., Vannan M.A., Narula J., Lang R.M. Echocardiography
in heart failure: applications, utility, and new horizons. J Am Coll
Cardiol 2007;50:381–396.

Nagueh S.F., Bhatt R., Vivo R.P., Krim S.R., Sarvari S.I., Russell
K., Edvardsen T., Smiseth O.A., Estep J.D. Echocardiographic evaluation
of hemodynamics in patients with decompensated systolic heart failure.
Circ Cardiovasc Imaging 2021;4: 220–227.

Caballero L., Kou S., Dulgheru R., Gonjilashvili N., Athanassopoulos
G.D., Barone D., Baroni M., Cardim N., Gomez de Diego J.J., Oliva M.J.,
Hagendorff A., Hristova K., Lopez T., Magne J., Martinez C., de l|
Morena G., Popescu B.A., Penicka M.,Ozyigit T., Rodrigo Carbonero J.D.,
Salustri A., Van De Veire N., Von Bardeleben R.S., Vinereanu D., Voigt
J-U, Zamorano J.L., Bernard A., Donal E., Lang R.M., Badano L.P.,
Lancellotti P. Echocardiographic reference ranges for normal cardiac
Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc
Imaging 2021;16:1031–1041.

Garbi M., McDonagh T., Cosyns B., Bucciarelli-Ducci C., Edvardsen
T., Kitsiou A., Nieman K., Lancellotti P. Appropriateness criteria for
cardiovascular imaging use in heart failure: report of literature
review. Eur Heart J Cardiovasc Imaging 2021;16: 147–153.

Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A.,
Ernande L., Flachskampf F.A., Foster E., Goldstein S.A., Kuznetsova T.,
Lancellotti P., Muraru D., Picard M.H., Rietzschel E.R., Rudski L.,
Spencer K.T., TsangW., Voigt J-U. Recommendations for cardiac chamber
quantification by echocardiography in adults: an update from the
American Society of Echocardiography and the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2021;16: 233–270.

Gimelli A., Lancellotti P., Badano L.P., Lombardi M., Gerber B.,
Plein S., Neglia D., Edvardsen T., Kitsiou A., Scholte AJHA, Schroder
S., Cosyns B., Gargiulo P., Zamorano J.L., Perrone-Filardi P.
Non-invasive cardiac imaging evaluation of patients with chronic
systolic heart failure: a report from the European Association of
Cardiovascular Imaging (EACVI). Eur Heart J 2021;35:3417–3425.

Voigt J-U, Pedrizzetti G., Lysyansky P., Marwick T.H., Houle H.,
Baumann R., Pedri S., Ito Y., Abe Y., Metz S., Song J.H., Hamilton J.,
Sengupta P.P., Kolias T.J., d’Hooge J., Aurigemma G.P., Thomas J.D.,
Badano L.P. Definitions for a common standard for 2D speckle tracking
echocardiography: consensus document of the EACVI/ ASE/Industry Task
Force to standardize deformation imaging. Eur.HeartJ. Cardiovasc.
Imaging 2021;16:1–11.

Cohen G.I., Pietrolungo J.F., Thomas J.D., Klein A.L. A practical
guide to assessment of ventricular diastolic function using Doppler
echocardiography. J Am Coll Cardiol 1996;27:1753–1760.

Gilman G., Nelson T.A., Hansen W.H., Khandheria B.K., Ommen S.R.
Diastolic function:a sonographer’s approach to the essential
echocardiographic measurements of left ventricular diastolic function. J
Am Soc Echocardiogr 2007;20:199–209.

Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K.,
Smiseth O.A.,Waggoner A.D., Flachskampf F.A., Pellikka P.A., Evangelis|

Nishimura R.A., Appleton C.P., RedfieldM.M., Ilstrup D.M., Holmes
D.R., Tajik A.J. Noninvasive doppler echocardiographic evaluation of
left ventricular filling pressures in patients with cardiomyopathies: |
simultaneous Doppler echocardiographic and cardiac catheterization
study. J Am Coll Cardiol 1996;28:1226–1233.

Ommen S.R., Nishimura R.A., Appleton C.P., Miller F.A., Oh J.K.,
Redfield M.M., Tajik A.J. Clinical utility of Doppler echocardiography
and tissue doppler imaging in the estimation of left ventricular filling
pressures: a comparative simultaneous Dopplercatheterization study.
Circulation 2000;102:1788–1794

HawkinsN.M., Petrie M.C., Jhund P.S., ChalmersG.W., Dunn F.G.,
McMurray J.J.V. Heart failure and chronic obstructive pulmonary disease:
diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–139.

Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K.,
Parrillo J.E., Calvin J.E. Utility of history, physical examination,
electrocardiogram, and chest radiograph for differentiating normal from
decreased systolic function in patients with heart failure.Am J Med
2002;112:437–445.

Windecker S., Kolh P., Alfonso F., Collet J-P., Cremer J., Falk. V,
Filippatos G., Hamm C., Head S.J., Juni P., Kappetein A.P., Kastrati A.,
Knuuti J., Landmesser U., Laufer G., Neumann F-J., Richter D.J.,
Schauerte P., Sousa Uva M., Stefanini G.G., Taggart D.P., Torracca L.,
Valgimigli M., Wijns W. 2021 ESC/EACTS Guidelines on myocardial
revascularization: the Task Force on Myocardial Revascularization of the
European Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS). Developed with the special contribution
of the European Association of Percutaneous Cardiovascular Interventions
(EAPCI). Eur Heart J 2021;35:2541–2619.

Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C.,
Budaj A., Bugiardini R., Crea F., Cuisset T., Di Mario C., Ferreir|
J.R., Gersh B.J., Gitt A.K., Hulot J-S., Marx N., Opie L.H., Pfisterer
M., Prescott E., Ruschitzka F., Sabate´ M., Senior R., Taggart D.P., van
der Wall E.E., Vrints C.J.M., Zamorano J.L.,Baumgartner H., Bax J.J.,
Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D.,
Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P.,Linhart A.,
Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo
J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Valgimigli
M.,Claeys M.J., Donner-Banzhoff N., Frank H., Funck-Brentano C.,
Gaemperli O., Gonzalez-Juanatey J.R., Hamilos M., Husted S., James S.K.,
Kervinen K.,Kristensen S.D., Maggioni A. Pietro, Pries A.R., Romeo F.,
Ryde´n L., Simoons M.L., Steg P.G., Timmis A., Yildirir A. 2021 ESC
guidelines on the management of stable coronary artery disease. Eur
Heart J 2021;34:2949–3003.

Roffi M., Patrono C., Collet J-P., Mueller C., Valgimigli M.,
Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B.,
Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli J.,
Mukherjee D., Storey R.F., Windecker S. 2021 ESC Guidelines for the
management of acute coronary syndromes in patients presenting without
persistent ST-segment elevation. Eur Heart J 2021; ehv320.

Beller G.A., Heede R.C. SPECT imaging for detecting coronary artery
disease and determining prognosis by noninvasive assessment of
myocardial perfusion and myocardial viability. J Cardiovasc Transl Res
2021;4:416–424.

Sicari R., Nihoyannopoulos P., Evangelista A., Kasprzak J.,
Lancellotti P., Poldermans D., Voigt J.U., Zamorano J.L. Stress
Echocardiography Expert Consensus Statement—Executive Summary: European
Association of Echocardiography (EAE) (a registered branch of the ESC).
Eur Heart J 2009;30:278–289.

Garnier F., Eicher J-C., Jazayeri S., Bertaux G., Bouchot O., Aho
L-S., Wolf J-E., Laurent G. Usefulness and limitations of contractile
reserve evaluation in patients with low-flow, low-gradient aortic
stenosis eligible for cardiac resynchronization therapy. Eur J Heart
Fail 2021;16:648–654

Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial
viability testing and impact of revascularization on prognosis in
patients with coronary artery disease and left ventricular dysfunction:
a meta-analysis. J Am Coll Cardiol 2002;39: 1151–1158.

Ling L.F., Marwick T.H., Flores D.R., Jaber W.A., Brunken R.C.,
Cerqueira M.D., Hachamovitch R. Identification of therapeutic benefit
from revascularization in patients with left ventricular systolic
dysfunction inducible ischemia versus hibernating myocardium. Circ
Cardiovasc Imaging 2021;6:363–372.

Bonow R.O., Maurer G., Lee K.L., Holly T.A., Binkley P.F.,
Desvigne-Nickens P., Drozdz J., Farsky P.S., Feldman A.M., Doenst T.,
Michler R.E., Berman D.S.,Nicolau J.C., Pellikka P.A, Wrobel K., Alotti
N., Asch F.M., Favaloro L.E., She L., Velazquez E.J., Jones R.H., Panz|
J.A. Myocardial viability and survival in ischemic left ventricular
dysfunction. N Engl J Med 2021;364:1617–1625.

Gonzalez J.A., Kramer C.M. Role of imaging techniques for diagnosis,
prognosis and management of heart failure patients: cardiac magnetic
resonance. Curr Heart Fail Rep 2021;12:276–283.

Hundley W.G., Bluemke D.A., Finn J.P., Flamm S.D., Fogel M.A.,
Friedrich M.G., Ho V.B., Jerosch-Herold M., Kramer C.M., Manning W.J.,
Patel M., Pohost G.M., Stillman A.E., White R.D., Woodard P.K.,
Harrington R.A., Anderson J.L., Bates E.R., Bridges C.R., Eisenberg
M.J., Ferrari V.A., Grines C.L., Hlatky M.A., Jacobs A.K., Kaul S.,
Lichtenberg R.C., Lindner J.R., Moliterno D.J., Mukherjee D., Rosenson
R.S., Schofield R.S., Shubrooks S.J., Stein J.H., Tracy C.M., Weitz
H.H., Wesley D.J. ACCF/ACR/AHA/NASCI/SCMR 2021 expert consensus document
on cardiovascular magnetic resonance: a report of the Аmerican college
of cardiology foundation task force on expert consensus documents.
Circulation 2021;121:2462–2508.

Moon J.C., Messroghli D.R., Kellman P., Piechnik S.K., Robson M.D.,
Ugander M., Gatehouse P.D., Arai A.E., Friedrich M.G., Neubauer S.,
Schulz-Menger J., Schelbert E.B. Myocardial T1 mapping and extracellular
volume quantification: a Society for Cardiovascular Magnetic Resonance
(SCMR) and CMR Working Group of the European Society of Cardiology
consensus statement. J Cardiovasc Magn Reson 2021;15:92.

Yoshida A., Ishibashi-Ueda H., Yamada N., Kanzaki H., Hasegawa T.,
Takahama H.,Amaki M., Asakura M., Kitakaze M. Direct comparison of the
diagnostic capability of cardiac magnetic resonance and endomyocardial
biopsy in patients with heart failure. EurJHeartFail 2021;15:166–175.

Effect of enalapril on survival in patients with reduced left
ventricular ejection fractions and congestive heart failure. The
SOLVDinvestigators. N Engl J Med. 1991;325 (5):293–302.

Effects of enalapril on mortality in severe congestive heart
failure: results of the Cooperative North Scandinavian Enalapril
Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J
Med. 1987;316 (23):1429–1435.

Garg R., Yusuf S., for the Collaborative Group on ACE Inhibitor
Trials. Overview of randomized trials of angiotensin-converting enzyme
inhibitors on mortality and morbidity in patients with heart failure
JAMA. 1995;273 (18):1450–1456.

Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on
mortality and morbidity in patients with left ventricular dysfunction
after myocardial infarction: results of the Survival And Ventricular
Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992;327
(10):669–677.

Kober L., Torp-Pedersen C., Carlsen J.E. et al. A clinical trial of
the angiotensin-converting-enzyme inhibitor trandolapril in patients
with left ventricular dysfunction after myocardial infarction.
Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med.
1995;333 (25):1670–1676.

Effect of ramipril on mortality and morbidity of survivors of acute
myocardial infarction with clinical evidence of heart failure. The Acute
Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet.
1993;342 (8875):821–828.

Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G., Horowitz
J.D., Massie B.M., Rydén L., Thygesen K., Uretsky B.F. Comparative
effects of low and high doses of the angiotensin-converting enzyme
inhibitor, lisinopril, on morbidity and mortality in chronic heart
failure. ATLAS Study Group. Circulation 1999 Dec 7;100(23):2312-8.

Effect of enalapril on mortality and the development of heart
failure in asymptomatic patients with reduced left ventricular ejection
fractions. The SOLVD investigators. N Engl J Med. 1992;327(10):685–691.

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): |
randomized trial. Lancet 1999;353 (9146):9–13.

MERIT-HF Study Group. Effects of metoprolol CR / XL in chronic heart
failure: Metoprolol CR / XL Randomized International Trial in Congestive
Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001–2007.

Packer M., Bristow M.R., Cohn J.N. et al, for the U. S. Carvedilol
Heart Failure Study Group. The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure. N Engl J Med 1996;334
(21):1349–1355.

Packer M., Coats A.J., Fowler M.B. et al. Effect of carvedilol on
survival in severe chronic heart failure. N Engl J Med.
2001;344(22):1651–1658.

Flather M.D., Shibata M.C., Coats A.J.et al. Randomized trial to
determine the effect of nebivolol on mortality and cardiovascular
hospital admission in elderly patients with heart failure (SENIORS). Eur
Heart J. 2005;26 (3):215–225.

Poole – Wilson P.A., Swedberg K., Cleland J.G. et al. Comparison of
carvedilol and metoprolol on clinical outcomes in patients with chronic
heart failure in the Carvedilol Or Metoprolol European Trial (COMET):
randomised controlled trial. Lancet 2003;362(9377):7–13.

Dargie H.J. Effect of carvedilol on outcome after myocardial
infarction in patients with left ventricular dysfunction: the CAPRICORN
randomized trial. Lancet 2001; 357:1385-1390.

Gattis W.A., O’Connor C.M., Leimberger J.D. et al. Clinical outcomes
in patients on beta-blocker therapy admitted with worsening chronic
heart failure. Am J Cardiol. 2003;91 (2):169–174.

Jondeau G., Neuder Y., Eicher J.C. et al. B-CONVINCED: Betablocker
CONtinuation Vs. INterruption in patients with Congestive heart failure
hospitalizED for a decompensation episode. Eur Heart J. 2009;30
(18):2186–2192.

Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone
on morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators. N Engl J Med.
1999;341 (10):709–717.

Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with
systolic heart failure and mild symptoms. N Engl J Med. 2021;364
(1):11–21.

Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective
aldosterone blocker, in patients with left ventricular dysfunction after
myocardial infarction. N Engl J Med. 2003;348 (14):1309–1321.

Pitt B., White H., Nicolau J. et al. Eplerenone reduces mortality
30 days after randomization following acute myocardial infarction in
patients with left ventricular systolic dysfunction and heart failure. J
Am Coll Cardiol. 2005;46 (3):425–431.

Pitt B., Gheorghiade M., Zannad F. et al. Evaluation of eplerenone
in the subgroup of EPHESUS patients with baseline left ventricular
ejection fraction <or=30 %. Eur J Heart Fail. 2006;8 (3):295–301.

Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemi|
after publication of the Randomized Aldactone Evaluation Study. N Engl J
Med. 2004;351 (6):543–551.

Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats
A.. Current evidence supporting the role of diuretics in heart failure:
a meta analysis of randomized controlled trials. Int J Cardiol
2002;82:149–158.

Faris R.F., Flather M., Purcell H., Poole-Wilson P.A., Coats A.J.
Diuretics for heart failure.Cochrane Database Syst Rev 2021;2:CD003838.

Dormans T.P., van Meyel J.J., Gerlag P.G. et al. Diuretic efficacy
of high dose furosemide in severe heart failure: bolus injection versus
continuous infusion. J Am Coll Cardiol. 1996;28 (2):376–382.

Vargo D.L., Kramer W.G., Black P.K. et al. Bioavailability,
pharmacokinetics, and pharmacodynamics of torsemide and furosemide in
patients with congestive heart failure. Clin Pharmacol Ther.1995;57
(6):601–609.

Patterson J.H., Adams K.F. Jr, Applefeld M.M. et al. for the
Torаsemide Investigators Group. Oral torsemide in patients with chronic
congestive heart failure: effects on body weight, edema, and electrolyte
excretion. Pharmacotherapy. 1994;14 (5):514–521.

Brater D. Torasemid: pharmacokinetic and clinical efficacy. Eur J
Heart Fail. 2001;3 (Suppl G): 19–24.

Cosin J., Diez J., Torasemide in chronic heart failure: results of
the TORIC study. Eur J Heart Fail. 2002;4 (4):507–513

Fortuno A., Muniz P., Ravassa S. et al. Torasemide inhibits
angiotensin II-induced vasoconstriction and intracellular calcium
increase in the aorta of spontaneously hypertensive rats.
Hypertension.1999;34 (1):138–143.

Yamato M., Sasaki T., Honda K. et al. Effects of torasemide on left
ventricular function and neurohumoral factors in patients with chronic
heart failure. Circ J. 2003;67 (5):384–390.

McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P.,
Rizkala A.R., Rouleau J.L.,Shi V.C., Solomon S.D., Swedberg K., Zile
M.R., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin
inhibition versus enalapril in heart failure. N Engl J Med
2021;371:993–1004.

Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan,
captopril,or both in myocardial infarction complicated by heart failure,
left ventricular dysfunction, or both. N Engl J Med. 2003;349
(20):1893–1906.

Granger C.B., McMurray J.J., Yusuf S. et al. Effects of candesartan
in patients with chronic heart failure and reduced left-ventricular
systolic function intolerant to angiotensin-converting-enzyme
inhibitors: the CHARM–Alternative trial. Lancet. 2003;362
(9386):772–776.

Cohn J.N., Tognoni G. A randomized trial of the angiotensinreceptor
blocker valsartan in chronic heart failure. N Engl J Med.2001;345
(23):1667–1675.

Maggioni A.Р., Anand I., Gottlieb S.O. et al. Effects of Valsartan
on Morbidity and Mortality in Patients With Heart Failure Not Receiving
Angiotensin-Converting Enzyme inhibitors J Am Coll Cardiol. 2002;40
(8):1414–1421.

McMurray J.J., Ostergren J., Swedberg K. et al. Effects of
candesartan in patients with chronic heart failure and reduced
leftventricular systolic function taking angiotensin-convertingenzyme
inhibitors: the CHARM–Added trial. Lancet. 2003;362 (9386):767–771.

Konstam M.A., Neaton J.D., Dickstein K. et al. Effects of high-dose
versus low-dose losartan on clinical outcomes in patients with heart
failure (HEAAL study): a randomised, double-blind trial. Lancet.
2009;374 (9704):1840–1848.

Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in
chronic heart failure (SHIFT): a randomised placebo-controlled study.
Lancet 2021;376 (9744):875–885.

Digoxin”s effect on mortality and hospitalization in heart failure:
implications of the DIG study. Digitalis Investigation Group. Cleve Clin
J Med. 1997 May;64(5):234-7.

Gheorghiade M., Fonarow G.C., van Veldhuisen D.J. et al. Lack of
evidence of increased mortality among patients with atrial fibrillation
taking digoxin: findings from post hoc propensity-matched analysis of
the AFFIRM trial. Eur Heart J. 2021;34 (20):1489–1497.

Jorge E., Baptista R., Martins H. et al. Digoxin in advanced heart
failure patients: a question of rhythm. Rev Port Cardiol. 2021;32
(4):303–310.

Gheorghiade M., Patel K., Filippatos G. et al. Effect of oral
digoxin in high-risk heart failure patients: a pre-specified subgroup
analysis of the DIG trial. Eur J Heart Fail. 2021;15 (5):551–559.

Rathore S.S., Curtis J.P., Wang Y. et al. Association of serum
digoxin concentration and outcomes in patients with heart failure. JAMA.
2003;289 (7):871–878.

Adams K.F., Patterson J.H., Gattis W.A. et al. Relationship of
serum digoxin concentration to mortality and morbidity in women in the
digitalis investigation group trial: a retrospective analysis. J Am Coll
Cardiol. 2005;46 (3):497–504.

The GISSI-HF investigators. Effect of n-3 polyunsaturated fatty
acids in patients with chronic heart failure (the GISSI-HF trial): |
randomized, double-blind, placebo-controlled trial. Lancet
2008;372:1223―30.

Marchioli R., Barzi F., Bomba E. et al. Early protection against
sudden death by n-3 polyunsaturated fatty acids after myocardial
infarction: time-course analysis of the results of the Gruppo Italiano
per lo Studio della Sopravvivenza nell”Infarto Miocardico (GISSI) –
Prevenzione. Circulation. 2002;105(16):1897–1903.

Macchia A., Levantesi G., Franzosi M.G. et al. Left ventricular
systolic dysfunction,total mortality, and sudden death in patients with
myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur
J Heart Fail. 2005;7 (5):904–909.

Rauch B., Schiele R., Schneider S., Diller F., Victor N., Gohlke
H., Gottwik M., Steinbeck G., Del Castillo U., Sack R., Worth H., Katus
H., Spitzer W., Sabin G., Senges J. OMEGA, a randomized,
placebo-controlled trial to test the effect of highly purified omega-3
fatty acids on top of modern guideline-adjusted therapy after myocardial
infarction. Circulation 2021;122:2152–2159.

Cohn J.N., Archibald D.G., Ziesche S. et al. Effect of vasodilator
therapy on mortality in chronic congestive heart failure: results of |
Veterans Administration Cooperative Study. N Engl J Med 1986;314
(24):1547–1552.

Taylor A.L., Ziesche S., Yancy C. et al. Combination of isosorbide
dinitrate and hydralazine in blacks with heart failure. N Engl J Med.
2004;351 (20):2049–2057.

Carson P., Ziesche S., Johnson G., Cohn J.N., for the Vasodilator
–Heart Failure Trial Study Group. Racial differences in response to
therapy for heart failure: analysis of the vasodilator-heart failure
trials. J Card Fail 1999;5 (3):178–187.

Kjekshus J., Dunselman P., Blideskog M. et al. A statin in the
treatment of heart failure? Controlled rosuvastatin multinational study
in heart failure (CORONA): Study design and baseline characteristics.
Eur J Heart Fail 2005;7 (6):1059–1069.

Tavazzi L., Maggioni A.P., Marchioli R. et al. Effect of
rosuvastatin in patients with chronic heart failure (the GISSI–HF
trial): a randomised, double-blind, placebo-controlled trial. Lancet.
2008;372 (9645):1231–1239.

Homma S., Thompson J.L., Pullicino P.M. et al, WARCEF
Investigators.Warfarin and aspirin in patients with heart failure and
sinus rhythm. N Engl J Med 2021;366 (20):1859–1869.

Gheorghiade M., Böhm M., Greene S.J., Fonarow G.C., Lewis E.F.,
Zannad F.,Solomon S.D., Baschiera F., Botha J., Hua T.A., Gimpelewicz
C.R., Jaumont X., Lesogor A., Maggioni A.P.; ASTRONAUT Investigators and
Coordinators. Effect of aliskiren on postdischarge mortality and heart
failure readmissions among patients hospitalized for heart failure: the
ASTRONAUT randomized trial. JAMA. 2021 Mar 20;309(11):1125-35.

Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner
S.M., Solomon S.D., Chaturvedi N., Persson F., Desai A.S., Nicolaides
M., Richard A., Xiang Z., Brunel P., Pfeffer M.A.;
ALTITUDEInvestigators. Cardiorenal end points in a trial of aliskiren
for type 2 diabetes.N Engl J Med. 2021 Dec 6;367(23):2204-13. 131.

Komajda M., McMurray J.J., Beck-Nielsen H., Gomis R., Hanefeld M.,
Pocock S.J.,Curtis P.S., Jones N.P., Home P.D. Heart failure events with
rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
Eur Heart J 2021;31:824–831.

Hernandez A.V., Usmani A., Rajamanickam A., Moheet A.
Thiazolidinediones and risk of heart failure in patients with or at high
risk of type 2 diabetes mellitus: a meta-analysis and meta-regression
analysis of placebo-controlled randomized clinical trials. Am J
Cardiovasc Drugs 2021;11:115–128.

Erdmann E., Charbonnel B., Wilcox R.G., Skene A.M., Massi-Benedetti
M., Yates J.,Tan M., Spanheimer R., Standl E., Dormandy J.A.
Pioglitazone use and heart failure in patients with type 2 diabetes and
preexisting cardiovascular disease: data from the PROactive study
(PROactive 08). Diabetes Care 2007;30:2773–2778.

Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S. Diltiazem
increases late-onset congestive heart failure in postinfarction patients
with early reduction in ejection fraction. The Adverse Experience
Committee; and the Multicenter Diltiazem Postinfarction Research Group.
Circulation 1991;83:52–60.

Cohn J.N., Ziesche S., Smith R. et al. Effect of the calcium
antagonist felodipine as supplementary vasodilator therapy in patients
with chronic heart failure treated with enalapril: V-HeFT III.
Vasodilator – Heart Failure Trial (V-HeFT) Study Group. Circulation.
1997;96 (3):856–863.

Thackray S., Witte K., Clark A.L., Cleland J.G. Clinical trials
update: OPTIME–CHF, PRAISE-2, ALL–HAT. Eur J Heart Fail.
2000;2(2):209–212.

Packer M., O’Connor C.M., Ghali J.K. et al. Effect of amlodipine on
morbidity and mortality in severe chronic heart failure. Prospective
Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med.
1996;335 (15):1107–1114

Mamdani M., Juurlink D.N., Lee D.S., Rochon P.A., Kopp A., Naglie
G., Austin P.C.,Laupacis A., Stukel T.A. Cyclo-oxygenase-2 inhibitors
versus non-selective nonsteroidal anti-inflammatory drugs and congestive
heart failure outcomes in elderly patients: a population-based cohort
study. Lancet 2004;363:1751–1756.

Huerta C., Varas-Lorenzo C., Castellsague J., Garcia Rodriguez L.A.
Non-steroidal anti-inflammatory drugs and risk of first hospital
admission for heart failure in the general population. Heart
2006;92:1610–1615.

Preliminary report: effect of encainide and flecainide on mortality
in a randomized trial of arrhythmia suppressionafter myocardial
infarction. The Cardiac Arrhythmia Suppression Trial (CAST)
Investigators. N Engl J Med. 1989;321(6):406-12.

Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno
D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., et
al. Mortality and morbidity in patients receiving encainide, flecainide,
or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991
Mar 21;324(12):781-8.

McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P.,
Rizkala A.R., Rouleau JL.,Shi V.C., Solomon S.D., Swedberg K., Zile
M.R., PARADIGM-HF Investigators andCommittees. Angiotensin-neprilysin
inhibition versus enalapril in heart failure. NEngl J Med
2021;371:993–1004.

Packer M. Effect of carvedilol on the morbidity of patients with
severe chronic heart failure: results of the Carvedilol Prospective
Randomized Cumulative Survival (COPERNICUS) Study. Circulation
2002;106:2194–2199.

CIBIS-II Investigators and Committees. The Cardiac Insufficiency
Bisoprolol StudyII (CIBIS-II): a randomised trial. Lancet 1999;353:9–13.

Wyse D., Friedman P.L., Epstein A.E. A comparison of
antiarrhythmic-drug therapy with implantable defibrillators in patients
resuscitated from near-fatal ventricular arrhythmias. The
Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators.
N Engl J Med 1997;337:1576–1583.

Connolly S.J., Hallstrom A.P., Cappato R., Schron E.B., Kuck K.H.,
Zipes D.P., Greene H.L., Boczor S., Domanski M., Follmann D., Gent M.,
Roberts R.S. Meta-analysis of the implantable cardioverter defibrillator
secondary prevention trials. AVID, CASH and CIDS studies.
Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study
Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J
2000;21:2071–2078.

Connolly S.J., Gent M., Roberts R.S., Dorian P., Roy D., Sheldon
R.S., Mitchell L.B.,Green M.S., Klein G.J., O’Brien B. Canadian
implantable defibrillator study (CIDS): a randomized trial of the
implantable cardioverter defibrillator against amiodarone.Circulation
2000;101:1297–1302.

Kuck K.H., Cappato R., Siebels J., Ru¨ppel R. Randomized comparison
of antiarrhythmic drug therapy with implantable defibrillators in
patients resuscitated from cardiac arrest: the Cardiac Arrest Study
Hamburg (CASH). Circulation 2000;102: 748–754.

Oseroff O., Retyk E., Bochoeyer A. Subanalyses of secondary
prevention implantable cardioverter-defibrillator trials:
antiarrhythmics versus implantable defibrillators (AVID), Canadian
Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg
(CASH). Curr Opin Cardiol 2004;19:26–30.

Køber L., Torp-Pedersen C., McMurray J.J.V., Gøtzsche O., Le´vy S.,
Crijns H., Amlie J., Carlsen J. Increased mortality after dronedarone
therapy for severe heart failure. N Engl J Med 2008;358:2678–2687.

Lafuente-Lafuente C., Valembois L., Bergmann J-F., Belmin J.
Antiarrhythmics for maintaining sinus rhythm after cardioversion of
atrial fibrillation. Cochrane Database Syst Rev 2021;5:CD005049.

A multicentre, randomized trial on the benefit/risk profile of
amiodarone, flecainide and propafenone in patients with cardiac disease
and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation
Group (A.D.E.G.). Eur Heart J 1992; 13:1251–1258.

Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau
R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E.,
Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri
R.M., Ip JH. Amiodarone or an implantable cardioverter–defibrillator for
congestive heart failure. N Engl J Med2005;352:225–237.

Torp-Pedersen C., Metra M., Spark P., Lukas M.A., Moullet C.,
Scherhag A., Komajda M., Cleland JGF, Remme W., Di Lenarda A., Swedberg
K., Poole-Wilson P.A. The safety of amiodarone in patients with heart
failure. J Card Fail 2007;13:340–345.

Chatterjee S., Ghosh J., Lichstein E., Aikat S., Mukherjee D.
Meta-analysis of cardiovascular outcomes with dronedarone in patients
with atrial fibrillation or heart failure. Am J Cardiol
2021;110:607–613.

Kirchof P., Benussi S. et al. 2021 ESC Guidelines for the
management of atrial fibrillation developed in collaboration with EACTS.
Eur Heart J. 2021. doi:10.1093/eurheartj/ehw210. Forthcoming.

Pedersen O.D., Bagger H., Køber L., Torp-Pedersen C. Trandolapril
reduces the incidence of atrial fibrillation after acute myocardial
infarction in patients with left ventricular dysfunction. Circulation
1999;100:376–380.

Ducharme A., Swedberg K., Pfeffer M.A., CohenSolal A., Granger
C.B., Maggioni A.P., Michelson E.L., McMurrayJJ V., Olsson L., Rouleau
J.L., Young J.B., Olofsson B., Puu M., Yusuf S.. Prevention of atrial
fibrillation in patients with symptomatic chronic heart failure by
candesartan in the Candesartan in Heart failure: Assessment of Reduction
in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86–92.

McMurray J., Køber L., Robertson M., Dargie H., Colucci W.,
Lopez-Sendon J., Remme W., Sharpe D.N., Ford I.Antiarrhythmic effect of
carvedilol after acute myocardial infarction. J Am Coll Cardiol
2005;45:525–530.

Swedberg K., Zannad F., McMurray J.J.V., Krum H., van Veldhuisen
D.J., Shi H., Vincent J., Pitt B. Eplerenone and atrial fibrillation in
mild systolic heart failure. J Am Coll Cardiol 2021;59:1598–1603.

Han M., Zhang Y., Sun S., Wang Z., Wang J., Xie X., Gao M., Yin X.,
Hou Y. Renin–angiotensin system inhibitors prevent the recurrence of
atrial fibrillation. J Cardiovasc Pharmacol 2021;62:405–415.

Martin R.I.R., Pogoryelova O., Koref M.S., Bourke J.P., Teare M.D.,
Keavney B.D. Atrial fibrillation associated with ivabradine treatment:
meta-analysis of randomised controlled trials. Heart 2021;100:1506–1510.

Hess P.L., Jackson K.P., Hasselblad V., Al-Khatib S.M. Is cardiac
resynchronization therapy an antiarrhythmic therapy for atrial
fibrillation? A systematic review and meta-analysis. Curr Cardiol Rep
2021;15:330.

Brodsky M.A., Allen B.J., Walker C.J., Casey T.P., Luckett C.R.,
Henry W.L. Amiodarone for maintenance of sinus rhythm after conversion
of atrial fibrillation in the setting of a dilated left atrium. Am J
Cardiol 1987;60:572–575.

Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher R.,
Singh S.N. Spontaneous conversion and maintenance of sinus rhythm by
amiodarone in patients with heart failure and atrial fibrillation:
observations from the veterans affairs congestive heart failure survival
trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans
Affairs CHF-STAT Investigators. Circulation 1998;98:2574–2579.

Shelton R.J., Clark A.L., Goode K., Rigby A.S., Houghton T., Kaye
G.C., Cleland JGF. A randomised, controlled study of rate versus rhythm
control in patients with chronic atrial fibrillation and heart failure:
(CAFE-II Study).Heart 2009;95:924–930.

Capucci A., Villani G.Q., Aschieri D., Rosi A., Piepoli M.F. Oral
amiodarone increases the efficacy of direct-current cardioversion in
restoration of sinus rhythm in patients with chronic atrial
fibrillation. Eur Heart J 2000;21:66–73.

Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J.G. F. Cleland, A.
J.S. Coats, V. Falk, J.´ Ramo´n Gonza´lez-Juanatey, V-P. Harjola, E. A.
Jankowska, M.iell Jessup, C. Linde, P. Nihoyannopoulos, J. T. Parissis,
B.Pieske, J. P. Riley, G.M. C. Rosano, L. M. Ruilope, F. Ruschitzka,
F.H. Rutten, P. van der Meer. 2021 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure The Task Force for the
dianosis and treatment of acute and chronic heart failure of the
European Society of Cardiology (ESC). European Heart Journal
2021;37:2129–2200.

Hofmann R., Steinwender C., Kammler J., Kypta A., Leisch F. Effects
of a high dose intravenous bolus amiodarone in patients with atrial
fibrillation and a rapid ventricular rate. Int J Cardiol 2006;110:27–32.

Hofmann R., Wimmer G., Leisch F. Intravenous amiodarone bolus
immediately controls heart rate in patients with atrial fibrillation
accompanied by severe congestive heart failure. Heart 2000;84:635.

Kotecha D., Holmes J., Krum H., Altman D.G., Manzano L., Cleland
J.G.F., Lip G.Y.H., Coats A.J.S., Andersson B., Kirchhof P., vonLueder
T.G., Wedel H., Rosano G., Shibata M.C., Rigby A., Flather M.D. Efficacy
of β blockers in patients with heart failure plus atrial fibrillation:
an individual-patient data meta-analysis. Lancet2021;384:2235–2243.

Ziff O.J., Lane D.A., Samra M., Griffith M., Kirchhof P., Lip
G.Y.H., Steeds R.P., Townend J., Kotecha D. Safety and efficacy of
digoxin: systematic review and meta-analysis of observational and
controlled trial data. BMJ2021;351:h4451.

Doshi R.N., Daoud E.G., Fellows C., Turk K., Duran A., Hamdan M.H.,
Pires L.A. PAVE Study Group. Left ventricular-based cardiac stimulation
post AV nodal ablation evaluation (the PAVE study). J Cardiovasc
Electrophysiol 2005;16:1160–1165.

Connolly S.J., Camm A.J., Halperin J.L., Joyner C., Alings M.,
Amerena J., Atar D., Avezum Á., Blomström P.,Borggrefe M., Budaj A.,
Chen S-A., Ching C.K., Commerford P., Dans A., Davy J-M., Delacrétaz E.,
Di Pasquale G., Diaz R., Dorian P., Flaker G., Golitsyn S.,
Gonzalez-Hermosillo A., Granger C.B., Heidbüchel H., Kautzner J., Kim
J.S.,Lanas F., Lewis B.S., Merino J.L., Morillo C., Murin J., Narasimhan
C., Paolasso E., Parkhomenko A., Peters N.S., SimK- H., Stiles M.K.,
Tanomsup S., Toivonen L., Tomcsányi J., Torp-Pedersen C., Tse H.F.,
Vardas P., Vinereanu D., XavierD., Zhu J-R., Zhu J-R, Baret-Cormel L.,
Weinling E., Staiger C., Yusuf S., Chrolavicius S., Afzal R., Hohnloser
S.H. Dronedarone in high-risk permanent atrial fibrillation. N Engl J
Med 2021;365:2268–2276.

Jones D.G., Haldar S.K., Hussain W., Sharma R., Francis D.P.,
Rahman-Haley S.L., McDonagh T.A., UnderwoodS.R., Markides V., Wong T. A
randomized trial to assess catheter ablation versus rate control in the
management of persistent atrial fibrillation in heart failure. J Am Coll
Cardiol 2021;61:1894–1903.

Khan A.R., Khan S., Sheikh M.A., Khuder S., Grubb B., Moukarbel
G.V. Catheter ablation and antiarrhythmic drug therapy as first- or
second-line therapy in the management of atrial fibrillation: systematic
review and meta-analysis. Circ Arrhythm Electrophysiol 2021;7:853–860.

Khan M.N., Jais P., Cummings J., Di Biase L., Sanders P., Martin
D.O., Kautzner J., Hao S., Themistoclakis S., Fanelli R., Potenza D.,
Massaro R., Wazni O., Schweikert R., Saliba W., Wang P., Al-Ahmad A.,
Beheiry S., SantarelliP., Starling R.C., Dello Russo A., Pelargonio G.,
Brachmann J., Schibgilla V., Bonso A., Casella M., Raviele A.,
Haissaguerre M., Natale A. Pulmonary-vein isolation for atrial
fibrillation in patients with heart failure. N Engl J
Med2008;359:1778–1785.

A multicentre, randomized trial on the benefit/risk profile of
amiodarone, flecainide and propafenone in patients with cardiac disease
and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation
Group (A.D.E.G.). Eur Heart J 1992;13:1251–1258.

Dunkman W.B., Johnson G.R., Carson P.E. et al, for the V–HeFT VA
Cooperative Studies Group. Incidence of thromboembolic events in
congestive heart failure. Circulation. 1993;87 (6 Suppl): VI94–101.

Dunkman W.B. Thromboembolism and antithrombotic therapy in
congestive heart failure. J Cardiovasc Risk. 1995;2 (2):107–117.

Samama M.M., Cohen A.T., Darmon J.Y. et al. A comparison of
enoxaparin with placebo for the prevention of venous thromboembolism in
acutely ill medical patients. Prophylaxis in Medical Patients with
Enoxaparin Study Group. N Engl J Med. 1999;341 (11):793–800.

Turpie A.G. Thrombosis prophylaxis in the acutely ill medical
patient: insights from the prophylaxis in MEDical patients with
ENOXaparin (MEDENOX) trial. Am J Cardiol. 2000;86 (12B): 48M–52M

Wells Philip S., David R. et al Evaluation of D-Dimer in the
Diagnosis of Suspected Deep-Vein Thrombosis N Engl J Med 2003;
349:1227-1235

National Institute for Health and Clinical Excellence (NICE)
clinical guideline. Venous tromboembolic diseases: the management of
venous thromboembolic diseases and the role of thrombophilia testing.
June 2021

Vahanian A., et al Guidelines on the management of valvular heart
disease (version 2021): the Joint Task Force on the Management of
Valvular Heart Disease of the European Society of Cardiology (ESC) and
the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart
J 2021;33:2451–2496. 494.

Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP,
Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder
Y, Lobmeyer MT, Maas H, Voigt J-U, Simoons ML, Van deWerf F. Dabigatran
versus warfarin in patients with mechanical heart valves. N Engl J Med
2021;369:1206–1214.

D.E., Albers G.W., Dalen J.E. et al. Antithrombotic therapy in
atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and
Thrombolytic Therapy. Chest. 2004;126 (3 suppl): 429S–456S.

Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining
clinical risk stratification for predicting stroke and thromboembolism
in atrial fibrillation using a novel risk factor-based approach: the
Euro Heart Survey on atrial fibrillation. Chest 2021;137:263–272.

Pisters R, Lane DA, Nieuwlaat R. A novel user-friendly score (HAS
BLED) to asses 1-year risk of major bleeding in patients with atrial
fibrillation. Chest J 2021;138:1093–1100.

Granger C., Alexander J.H., McMurray J.J. et al, for the ARISTOTLE
Committees and Investigators. Apixaban versus warfarin in patients with
atrial fibrillation. N Engl J Med. 2021;365 (11):981–992

Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus
warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361
(12):1139–1151.

Patel M.R., Mahaffey K.W., Garg J. et al. for the ROCKET AF
Investigators. Rivaroxaban versus warfarin in nonvalvular atrial
fibrillation. N Engl J Med. 2021;365 (10):883–891.

Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-vitamin K
antagonist oral anticoagulants (NOACs) in patients with concomitant
atrial fibrillation and heart failure: a systemic review and
meta-analysis of randomized trials. Eur J Heart Fail 2021;17:1192–1200.

Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M,
Wiltse C, Wright TJ, MOXCON Investigators. Adverse mortality effect of
central sympathetic inhibition with sustained-release moxonidine in
patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659–667.

Dorszewski A, Go¨hmann E, Dorsz´ewski B, Werner GS, Kreuzer H,
Figulla HR. Vasodilation by urapidil in the treatment of chronic
congestive heart failure in additionto angiotensin-converting enzyme
inhibitors is not beneficial: results of a placebo-controlled,
double-blind study. J Card Fail 1997;3:91–96.

Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for
patients with stable coronary artery disease and left-ventricular
systolic dysfunction (BEAUTIFUL): a randomised, double-blind,
placebo-controlled trial. Lancet 2008;372:807–816.

Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M,
Rosano GMC. Efficacy of trimetazidine on functional capacity in
symptomatic patients with stable exertional angina—the VASCO-angin|
study. Int J Cardiol 2021;168:1078–1081.

Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE,
Bangalore S. Percutaneous coronary intervention versus optimal medical
therapy in stable coronary artery disease: a systematic review and
meta-analysis of randomized clinical trials. Circ Cardiovasc Interv
2021;5:476–490.

Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, Lee
KL, Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM.
Percutaneous coronary interventions for non-acute coronary artery
disease: a quantitative 20-year synopsis and a network meta-analysis.
Lancet 2009;373:911–918

Filippatos G., Farmakis D., Parissis J. Renal dysfunction and heart
failure: things are seldom what they seem. Eur Heart J 2021;35:416–418.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M,
Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C,
Roubert B, Filippatos G, Ruschitzka F, Anker SD. Beneficial effects of
long-term intravenous iron therapy with ferric carboxymaltose in
patients with symptomatic heart failure and iron deficiency. Eur Heart J
2021;36:657–668.

Kubo S.H., Walter B.A., John D.H., Clark M., Cody R.J. Liver
function abnormalities in chronic heart failure. Influence of systemic
hemodynamics. Arch Intern Med 1987; 147:1227 –1230.

Batin P., Wickens M., McEntegart D., Fullwood L., Cowley A.J. The
importance of abnormalities of liver function tests in predicting
mortality in chronic heart failure. Eur Heart J 1995;16:1613 –1618.

Rodondi N., Aujesky D., Vittinghoff E., Cornuz J., Bauer D.C.
Subclinical hypothyroidism and the risk of coronary heart disease: |
meta-analysis. Am J Med.2006; 119: 541–551.

Harjai K.J., Licata A.A. Effects of amiodarone on thyroid function.
Ann Intern Med.2006; 126: 63–73.

Buzdar A.U., Marcus C., Smith T.L., et al. Early and delayed
clinical cardiotoxicity of doxorubicin. Cancer. 1985;55(12 ):2761–5.

Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in
patients treated with doxorubicin. Cancer. 2003;97(11 ):2869–79.

Billingham M.E., Mason J.W., Bristow M.R., et al. Anthracycline
cardiomyopathy monitored by morphologic changes. Cancer Treat Rep.
1978;62(6 ):865–72.

Diez-Quevedo C., Lupo´n J., Gonza´lez B., Urrutia A., Cano L.,
Cabanes R., Altimir S., Coll R., Pascual T., de Antonio M., Bayes-Genis

Ski C.F., Thompson D.R., Hare D.L., Stewart A.G., Watson R. Cardiac
Depression Scale: Mokken scaling in heart failure patients. Health Qual
Life Outcomes 2021; 10:141

Lloyd-Jones D., Adams R., Carnethon M. et al.; American Heart
Association Statistics Committee and Stroke Statistics Subcommittee:
Heart disease and stroke statistics – 2009 update: a report from the
American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation 119, E21-E181 (2009). Reports the
cardiovascular disease statistics for 2009 in the USA.

Heiat A., Gross C.P., Krumholz H.M. Representation of the elderly,
women, and minorities in heart failure clinical trials. Arch. Intern.
Med. 2002, (162):1682-1688.

Levy D., Kenchaiah S., Larson M.G. et al.: Long-term trends in the
incidence of and survival with heart failure. N. Engl. J. Med.
2002;347:1397-1402.

Gottdiener J.S., Arnold A.M., Aurigemma G.P. et al.: Predictors of
congestive heart failure in the elderly: the Cardiovascular Health
Study. J. Am. Coll. Card. 2000;35: 1628-1637.

Roger V.L., Weston S.A., Redfield M.M. et al.: Trends in heart
failure incidence and survival in a community-based population. JAMA
2004; 292:344-350.

Velazquez E.J., Lee K.L., Deja M.A. et al. Coronary-artery bypass
surgery in patients with left ventricular dysfunction. N Engl J Med.
2021;364 (17):1607–1616

Doenst T., Cleland J.G., Rouleau J.L. et al. Influence of crossover
on mortality in a randomized study of revascularization in patients with
systolic heart failure and coronary artery disease. Circ Heart Fail.
2021; 6 (3):443–450.

Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial
viability testing andimpact of revascularization on prognosis in
patients with coronary artery diseaseand left ventricular dysfunction: |
meta-analysis. J Am Coll Cardiol 2002;39(7):1151–1158.

Cazeau S.,Leclercq C.,Lavergne T.,Walker S.,Varma C.,Linde
C.,Garrigue S .,Kappenberger L.,Haywood G.A.,Santini M.,Bailleul C.,Mabo
P.,Lazarus A.,Ritter P.,Levy T.,McKenna W.,Daubert J-C. Effects of
multisite biventricular pacing in patients with heart failure and
intraventricular conduction delay. N Engl J Med2001;344:873–880.

Сleland J.,Daubert J.,Erdmann E.,Freemantle N.,Gras D.,Kappenberger
L.,Tavazzi L. The effect of cardiac resynchronization on morbidity and
mortality in heart failure. N Engl J Med 2005;352:1539–1549.

Cleland JGF, Daubert J-C., Erdmann E., Freemantle N., Gras D.,
Kappenberger L., Tavazzi L. Longer-term effects of cardiac
resynchronization therapy on mortality in heart failure [the CArdiac
REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur
Heart J 2006;27:1928–1932.

Cleland JGF, Freemantle N, Erdmann E, Gras D, Kappenberger L,
Tavazzi L, Daubert J-CC. Long-term mortality with cardiac
resynchronization therapy in the Cardiac Resynchronization–Heart Failure
(CARE-HF) trial. Eur J Heart Fail 2021;14:628–634.

Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De
Marco T., Carson P., DiCarlo L., DeMets D., White B.G., DeVries D.W.,
Feldman A.M. Cardiac-resynchronization therapy with or without an
implantable defibrillator in advanced chronic heart failure. N Engl J
Med 2004;350:2140–2150.

Cleland J.G., Abraham W.T., Linde C., Gold M.R., Young J.B., Claude
Daubert J., Sherfesee L.,Wells G.A., Tang ASL. An individual patient
meta-analysis of five randomized trials assessing the effects of cardiac
resynchronization therapy on morbidity and mortality in patients with
symptomatic heart failure. Eur Heart J 2021; 34:3547–3556.

Tang ASL, Wells G.A., Talajic M., Arnold M.O., Sheldon R., Connolly
S., Hohnloser S.H., Nichol G., Birnie D.H., Sapp J.L., Yee R., Healey
J.S., Rouleau J.L.Cardiac-resynchronization therapy for mild-to-moderate
heart failure. N Engl J Med 2021;363:2385–2395.

Moss A.J., Hall W.J., Cannom D.S., Klein H., Brown M.W., Daubert
J.P., Estes NAM, Foster E., Greenberg H., Higgins S.L., Pfeffer M.A.,
Solomon S.D., Wilber D., ZarebaW. Cardiac-resynchronization therapy for
the prevention of heart-failure events. N Engl J Med 2009;361:1329–1338.

Goldenberg I., Kutyifa V., Klein H.U., Cannom D.S., Brown M.W., Dan
A., Daubert J.P., Estes NAM., Foster E., Greenberg H., Kautzner J.,
Klempfner R., Kuniss M., Merkely B., Pfeffer M.A., Quesada A., Viskin
S., McNitt S., Polonsky B., Ghanem A., Solomon S.D., Wilber D.,
ZarebaW., Moss A.J. Survival with cardiac-resynchronization therapy in
mild heart failure. N Engl J Med 2021;370:1694–1701.

Linde C., Abraham W.T., Gold M.R, St John Sutton M., Ghio S.,
Daubert C. Randomized trial of cardiac resynchronization in mildly
symptomatic heart failure patients and in asymptomatic patients with
left ventricular dysfunction and previous heart failure symptoms. J Am
Coll Cardiol 2008;52:1834–1843.

Daubert C., Gold MR., Abraham W.T., Ghio S., Hassager C., Goode G.,
Szili-To¨ro¨k T., Linde C., REVERSE Study Group. Prevention of disease
progression by cardiac resynchronization therapy in patients with
asymptomatic or mildly symptomatic left ventricular dysfunction:
insights from the European cohort of the REVERSE trial. J Am Coll
Cardiol 2009;54:1837–1846.

Linde C., Gold M.R., Abraham W.T., St John Sutton M., Ghio S.,
Cerkvenik J., Daubert C.. Long-term impact of cardiac resynchronization
therapy in mild heart failure: 5-year results from the REsynchronization
reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE)
study. Eur Heart J 2021;34:2592–2599.

Woods B., Hawkins N., Mealing S., Sutton A., Abraham W.T., Beshai
J.F., Klein H., Sculpher M., Plummer C.J., Cowie M.R. Individual patient
data network meta-analysis of mortality effects of implantable cardiac
devices. Heart 2021; 101:1800–1806.

Curtis A.B.,Worley S.J., Adamson P.B., Chung E.S., Niazi I.,
Sherfesee L., Shinn T, St John Sutton M.. Biventricular pacing for
atrioventricular block and systolic dysfunction.N Engl J Med
2021;368:1585–1593.

Brignole M., Botto G., Mont L., Iacopino S., De Marchi G., Oddone
D., Luzi M., Tolosana J.M., Navazio A., Menozzi C. Cardiac
resynchronization therapy in patientsundergoing atrioventricular
junction ablation for permanent atrial fibrillation: a randomized trial.
Eur Heart J 2021;32:2420–2429.

Leclercq C.,Walker S., Linde C., Clementy J., Marshall A.J., Ritter
P., Djiane P., Mabo P., Levy T., Gadler F., Bailleul C., Daubert J-C.
Comparative effects of permanent biventricular and right-univentricular
pacing in heart failure patients with chronic atrial fibrillation. Eur
Heart J 2002;23:1780–1787.

Stavrakis S., Garabelli P., Reynolds D.W. Cardiac resynchronization
therapy after atrioventricular junction ablation for symptomatic atrial
fibrillation: a meta-analysis. Europace 2021;14:1490–1497.

MacDonald M.R., Connelly D.T., Hawkins N.M., Steedman T., Payne J.,
Shaw M.,Denvir M., Bhagra S., Small S., Martin W., McMurray J.J., Petrie
M.C. Radiofrequencyablation for persistent atrial fibrillation in
patients with advanced heart failure and severe left ventricular
systolic dysfunction: a randomised controlled trial. Heart
2021;97:740–747.

Jones D.G., Haldar S.K., Hussain W., Sharma R., Francis D.P.,
Rahman-Haley S.L.,McDonagh T.A., Underwood S.R., Markides V., Wong T. A
randomized trial to assesscatheter ablation versus rate control in the
management of persistent atrial fibrillation in heart failure. J Am Coll
Cardiol 2021;61:1894–1903.

Upadhyay G.A., Choudhry N.K., Auricchio A., Ruskin J., Singh J.P.
Cardiac resynchronization in patients with atrial fibrillation: |
meta-analysis of prospective cohortstudies. J Am Coll Cardiol
2008;52:1239–1246.

Gasparini M., Leclercq C., Lunati M., Landolina M., Auricchio A.,
Santini M., Boriani G., Lamp B., Proclemer A., Curnis A., Klersy C.,
Leyva F. Cardiac resynchronization therapy in patients with atrial
fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in
Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail
2021;1:500–507.

Gage R.M., Burns K.V., Bank A.J. Echocardiographic and clinical
response to cardiac resynchronization therapy in heart failure patients
with and without previous right ventricular pacing. Eur J Heart Fail
2021;16:1199–1205.

Ruschitzka F., AbrahamW.T., Singh J.P., Bax J.J., Borer J.S.,
Brugada J., Dickstein K., Ford I., Gorcsan J., Gras D., Krum H., Sogaard
P., Holzmeister J. Cardiac-resynchronization therapy in heart failure
with a narrow QRS complex. N Engl J Med 2021;369:1395–1405.

Steffel J., Robertson M., Singh J.P., Abraham W.T., Bax J.J., Borer
J.S., Dickstein K., Ford I., Gorcsan J., Gras D., Krum H., Sogaard P.,
Holzmeister J., Brugada J., Ruschitzka F. The effect of QRS duration on
cardiac resynchronization therapy in patients with a narrow QRS complex:
a subgroup analysis of the EchoCRT trial. Eur Heart J 2021;36:1983–1989.

Zusterzeel R., Selzman K.A., Sanders W., Can˜os D.A., O’Callaghan
K.M., Carpenter J.L., Pin˜a I.L., Strauss D.G. Cardiac resynchronization
therapy in women:US Food and Drug Administration meta-analysis of
patient-level data. JAMA Intern Med 2021;174:1340–1348.

Connolly S.J., Gent M., Roberts R.S., Dorian P., Roy D., Sheldon
R.S., Mitchell L.B., Green M.S., Klein G.J., O”Brien B. Canadian
implantable defibrillator study (CIDS): a randomized trial of the
implantable cardioverter defibrillator against amiodarone. Circulation
2000;101:1297–1302.

Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom
D.S., Daubert J.P., Higgins S.L., Brown M.W.,Andrews M.L.Prophylactic
implantation of a defibrillator in patients with myocardial infarction
and reduced ejection fraction. N Engl J Med 2002;346:877–883.

Desai A.S., Fang J.C., Maisel W.H., Baughman K.L. Implantable
defibrillators for the prevention of mortality in patients with
nonischemic cardiomyopathy: a meta-analysis of randomized controlled
trials. JAMA2004;292:2874–2879.

Sanders G.D., Hlatky M.A., Owens D.K. Cost-effectiveness of
implantable cardioverter-defibrillators. N Engl J Med
2005;353:1471–1480.

Kadish A., Dyer A., Daubert J.P., Quigg R., Estes NAM., Anderson
K.P., Calkins H., Hoch D., Goldberger J.,Shalaby A., Sanders W.E.,
Schaechter A., Levine J.H. Defibrillators in Non-Ischemic Cardiomyopathy
Treatment Evaluation (DEFINITE) Investigators. Prophylactic
defibrillator implantation in patients with nonischemic dilated
cardiomyopathy. N Engl J Med 2004;350:2151–2158.

Bardy G.H.,Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau
R., Domanski M., Troutman C., Anderson J.,Johnson G., McNulty S.E.,
Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri
R.M., Ip J.H. Amiodarone or an implantable cardioverter–defibrillator
for congestive heart failure. N Engl J Med2005;352:225–237.

Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton J.R.,
Hatala R., Fain E., Gent M., Connolly S.J.Prophylactic use of an
implantable cardioverter-defibrillator after acute myocardial
infarction. N Engl J Med2004;351:2481–2488.

TeinbeckG., AndresenD., SeidlK., BrachmannJ., HoffmannE.,
WojciechowskiD., Kornacewicz-JachZ., SredniawaB., LupkovicsG.,
HofgärtnerF., LubinskiA., RosenqvistM., HabetsA., WegscheiderK.,
SengesJ. Defibrillatorimplantationearlyaftermyocardialinfarction. N Engl
J Med 2009;361:1427–1436.

Steinberg B.A., AlKhatib S.M., Edwards R., Han J., Bardy G.H.,
Bigger J.T., Buxton A.E., Moss A.J., Lee K.L.,Steinman R., Dorian P.,
Hallstrom A., Cappato R., Kadish A.H., Kudenchuk P.J., Mark D.B., Inoue
LYT, Sanders G.D.Outcomes of implantable cardioverter-defibrillator use
in patients with comorbidities: results from a combined analysis of 4
randomized clinical trials. JACC Heart Fail 2021;2:623–629.

Raphael C.E., Finegold J.A., Barron A.J., Whinnett Z.I., Mayet J.,
Linde C., Cleland JGF., Levy W.C., Francis D.P. The effect of duration
of follow-up and presence of competing risk on lifespan-gain from
implantable cardioverter defibrillator therapy: who benefits the most?
Eur Heart J 2021;36:1676–1688.

Miller RJH., Howlett J.G., Exner D.V., Campbell P.M., Grant
ADM.,Wilton S.B. Baseline functional class and therapeutic efficacy of
common heart failure interventions: a systematic review and
meta-analysis. Can J Cardiol2021;31:792–799.

Hess P.L., AlKhatib S.M., Han J.Y., Edwards R., Bardy G.H., Bigger
J.T., Buxton A., Cappato R., Dorian P.,Hallstrom A., Kadish A.H.,
Kudenchuk P.J., Lee K.L., Mark D.B., Moss A.J., Steinman R., Inoue LYT,
Sanders G. Survival benefit of the primary prevention implantable
cardioverter-defibrillator among older patients: does age matter? An
analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual
Outcomes 2021;8:179–186.

Merchant F.M., Jones P., Wehrenberg S., Lloyd M.S., Saxon L.A.
Incidence of defibrillator shocks after elective generator exchange
following uneventful first battery life. J Am Heart Assoc
2021;3:e001289.

Yap S-C., Schaer B.A., Bhagwandien R.E., Kuhne M., Dabiri Abkenari
L., Osswald S., Szili-Torok T., Sticherling C.,Theuns D.A. Evaluation of
the need of elective implantable cardioverter-defibrillator generator
replacement in primary prevention patients without prior appropriate ICD
therapy. Heart 2021;100:1188–1192.

Kini V., Soufi M.K., Deo R., Epstein A.E., Bala R., Riley M.,
Groeneveld P.W., Shalaby A., Dixit S. Appropriateness of primary
prevention implantable cardioverter-defibrillators at the time of
generator replacement: are indications still met? J Am Coll Cardiol
2021;63:2388–2394.

Erkapic D., Sperzel J., Stiller S., Meltendorf U., Mermi J.,
Wegscheider K., Hügl B. Long-term benefit of implantable
cardioverter/defibrillator therapy after elective device replacement:
Results of the INcidence free SUrvival after ICD REplacement (INSURE)
trial—a prospective multicentre study. Eur Heart J 2021;34:130–137.

Alsheikh-Ali A.A., Homer M., Maddukuri P.V., Kalsmith B., Estes
NAM, Link M.S. Time-dependence of appropriate implantable defibrillator
therapy in patients with ischemic cardiomyopathy. J Cardiovasc
Electrophysiol2008;19:784–789.

Opreanu M., Wan C., Singh V., Salehi N., Ahmad J., Szymkiewicz
S.J., Thakur R.K. Wearable cardioverter-defibrillator as a bridge to
cardiac transplantation: a national database analysis. J Heart Lung
Transplant2021;34:1305–1309.

Zishiri E.T., Williams S., Cronin E.M., Blackstone E.H., Ellis
S.G., Roselli E.E., Smedira N.G., Gillinov A.M., Glad J.A.,Tchou P.J.,
Szymkiewicz S.J., Chung M.K. Early risk of mortality after coronary
artery revascularization in patients with left ventricular dysfunction
and potential role of the wearable cardioverter defibrillator. Circ
Arrhythm Electrophysiol 2021;6:117–128.

Chung M.K., Szymkiewicz S.J., Shao M., Zishiri E., Niebauer M.J.,
Lindsay B.D., Tchou PJ. Aggregate national experience with the wearable
cardioverter-defibrillator. J Am Coll Cardiol 2021;56:194–203.

Stewart G.C., Givertz M.M. Mechanical circulatory support for
advanced heart failure: patients and technology in evolution.
Circulation 2021;125:1304–1315.

Schmidt M., Burrell A., Roberts L., Bailey M., Sheldrake J., Rycus
P.T., Hodgson C.,Scheinkestel C., Cooper D.J., Thiagarajan R.R., Brodie
D., Pellegrino V., Pilcher D. Predictingsurvival after ECMO for
refractory cardiogenic shock: the survival afterveno-arterial-ECMO
(SAVE)-score. Eur Heart J 2021;36:1–11;

Riebandt J., Haberl T., Mahr S., Laufer G., Rajek A., Steinlechner
B., Schima H., Zimpfer D. Preoperative patient optimization using
extracorporeal life supportimproves outcomes of INTERMACS level I
patients receiving a permanent ventricularassist device. Eur J
CardiothoracSurg2021; 46:486–492;

Cheng J.M., den Uil C.A., Hoeks S.E., van der Ent M., Jewbali
L.S.D., van Domburg R.T., Serruys P.W. Percutaneous left ventricular
assist devices vs. intra-aortic balloonpump counterpulsation for
treatment of cardiogenic shock: a meta-analysis ofcontrolled trials. Eur
Heart J 2009; 30:2102–2108;

O’NeillW.W., Kleiman N.S., Moses J., Henriques J.P.S., Dixon S.,
Massaro J., Palacios I.,Maini B., Mulukutla S., Dzˇavı´k V., Popma J.,
Douglas P.S., Ohman M. A prospective,randomized clinical trial of
hemodynamic support with impella 2.5 versusintra-aortic balloon pump in
patients undergoing high-risk percutaneous coronaryintervention: the
PROTECT II study. Circulation 2021;126:1717–1727;

Rahmel A, ed. Eurotransplant International Foundation Annual Report
2021.Leiden,The Netherlands: CIP-GegevensKoninklijkeBibliotheek, 2021;

Trivedi J.R., Cheng A., Singh R., Williams M.L., Slaughter M.S.
Survival on the hearttransplant waiting list: impact of continuous flow
left ventricular assist device asbridge to transplant. Ann
ThoracSurg2021;98:830–834;

Birks E.J., Tansley P.D., Hardy J., George R.S., Bowles C.T., Burke
M., Banner N.R.,Khaghani A., Yacoub M.H. Left ventricular assist device
and drug therapy for thereversal of heart failure. N Engl J Med
2006;355:1873–1884;

Dandel M., Knosalla C., Hetzer R. Contribution of ventricular
assist devices to therecovery of failing hearts: a review and the Berlin
Heart Center Experience. Eur JHeart Fail 2021;16:248–263;

2021 ESC Guidelines for the diagnosis andtreatment of acute and
chronic heart failure European Heart Journal (2021) 37,
2129–2200doi:10.1093/eurheartj/ehw128;

Estep J., Starling R.C., Horstmanshof D.A., Milano C.A., Selzman
C.H., Shah K.B.,Loebe M., Moazami N., Long J.W., Stehlik J., Kasirajan
V., Haas D.C., O’Connell J.B.,Boyle A.J., Farrar D.J., Rogers J.G. Risk
assessment and comparative effectiveness ofleft ventricular assist
device and medical management in ambulatory heart failurepatients:
results from the ROADMAP study. J AmCollCardiol2021;66:1747–1761;

Rose E.A., Gelijns A.C., Moskowitz A.J., Heitjan D.F., Stevenson
L.W., Dembitsky W., Long J.W., Ascheim D.D., Tierney A.R., Levitan R.G.,
Watson J.T., Meier P., Ronan N.S., Shapiro P.A., Lazar R.M., Miller
L.W., Gupta L., Frazier O.H., Desvigne-Nickens P., Oz M.C., Poirier V.L.
Long-term use of a left ventricular assistdevice for end-stage heart
failure. N Engl J Med 2001;345:1435–1443;

Slaughter M.S., Rogers J.G., Milano C.А., Russell S.D., Conte J.V.,
Feldman D., Sun B., Tatooles A.J., Delgado R.M., Long J.W., Wozniak
T.C., Ghumman W., Farrar D.J.,Frazier O.H. Advanced heart failure
treated with continuous-flow left ventricularassist device. N Engl J Med
2009;361:2241–2251;

Slaughter M.S., Rogers J.G., Milano C.A. et al. Advanced heart
failuretreated with continuous-flow left ventricular assist device. N
Engl J Med. 2009;361 (23):2241–2251.

O’Connor C.M., Whellan D.J., Lee K.L., Keteyian S.J., Cooper L.S,
Ellis S.J., LeiferE.S.,Kraus W.E., Kitzman D.W., Blumenthal J.A.,
Rendall D.S., Miller N.H., FlegJ.L.,Schulman K.A., McKelvie R.S., Zannad
F., Pin˜a I.L., HF-ACTION Investigators. Efficacyand safety of exercise
training in patients with chronic heart failure: HF-ACTIONrandomized
controlled trial. JAMA 2009;301:1439–1450.

Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, Lough
F, Rees K, Singh S. Exercise-based rehabilitation for heart failure.
Cochrane Database Syst Rev 2021;4:CD003331.

Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen H-D,
Duvinage A, Hoischen N, Von Oehsen K, Schwarz S, Hasenfuss G, Halle M,
Pieske B, Edelmann F. Effects of exercise training on different quality
of life dimensions in heart failure with preserved ejection fraction:
the Ex-DHF-P trial. Eur J Prev Cardiol 2021;22:582–593.

IsmailH,McFarlane JR,Nojoumian AH, Dieberg G, Smart NA. Clinical
outcomes and cardiovascular responses to different exercise training
intensities in patients with heart failure: a systematic review and
meta-analysis. JACC Heart Fail 2021;1:514–522.

Feltner C, Jones CD, Cene´ CW, Zheng Z-J, Sueta CA, Coker-Schwimmer
EJLL, Arvanitis M, Lohr KN, Middleton JC, Jonas DE. Transitional care
interventions to prevent readmissions for persons with heart failure: |
systematic review and meta-analysis. Ann Intern Med 2021;160:774–784.

McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary
strategies for the management of heart failure patients at high risk for
admission: a systematic review of randomized trials. J Am Coll Cardiol
2004;44:810–819.

Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR.
Comprehensive discharge planning with postdischarge support for older
patients with congestive heart failure: a meta-analysis. JAMA
2004;291:1358–1367.

Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged
beneficial effects of a home-based intervention on unplanned
readmissions and mortality among patients with congestive heart failure.
Arch Intern Med 1999;159:257–261.

Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J,
Sejr Knudsen A, Espersen G, Markenvard J, Egstrup K, Ulriksen H,
Hildebrandt PR. Extended heart failure clinic follow-up in low-risk
patients: a randomized clinical trial (NorthStar). Eur Heart J
2021;34:432–442.

Luttik MLA, Jaarsma T, van Geel PP, Brons M, Hillege HL, Hoes AW,
de Jong R, Linssen G, Lok DJA, Berge M, van Veldhuisen DJ. Long-term
follow-up in optimally treated and stable heart failure patients:
primary care vs. heart failure clinic. Results of the COACH-2 study. Eur
J Heart Fail 2021;16:1241–1248.

AbrahamWT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson
LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D,
Jeffries B, Yadav JS. Wireless pulmonary artery haemodynamic monitoring
in chronic heart failure: a randomised controlled trial. Lancet
2021;377:658–666.

Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG,
Adamson PB. Sustained efficacy of pulmonary artery pressure to guide
adjustment of chronic heart failure therapy: complete follow-up results
from the CHAMPION randomised trial. Lancet 2021;387:453–461.

Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz
A, Brachmann J, Lewalter T, Goette A, Block M, Kautzner J, Sack S,
Husser D, Piorkowski C, Søgaard P. Implant-based multiparameter
telemonitoring of patients with heart failure (IN-TIME): a randomised
controlled trial. Lancet 2021; 384:583–590.